Low-dose IL-2 therapy for immune-related adverse events via Tfh/Treg balance modulation: a prospective cohort and murine model study
Pinpointing immune imbalance early in cancer patients suggests low-dose IL-2 might prevent serious side effects while preserving treatment benefits.
This prospective cohort study demonstrates that early Tfh/Treg imbalance is a mechanistic driver of immune-related adverse events in patients receiving checkpoint inhibitors, with predictive value at the gene expression level. Low-dose IL-2 corrects this imbalance in murine models while preserving antitumor activity, providing a mechanistically grounded therapeutic alternative to immunosuppression for irAE management.
What the study was
- Study design
- Prospective cohort + murine model
- Population
- Gastrointestinal cancer patients receiving anti-PD-1/PD-L1 therapy, with irAE vs no-irAE comparison; lupus mouse model and tumor-bearing C57BL/6J mice
- Sample size
- 26
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cancer Immunology, Immunotherapy
Why it surfaced
First prospective characterization of Tfh/Treg dynamics as mechanistic predictor of irAEs at the transcriptomic level, combined with murine proof-of-concept for LDIL-2 as a novel irAE therapeutic. irAE management is a critical bottleneck limiting immunotherapy dosing and duration in cancer. Small cohort (n=26) limits immediate clinical translation but provides strong rationale for larger study.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.